297 related articles for article (PubMed ID: 34073710)
1. Sex-Specific Cannabidiol- and Iloperidone-Induced Neuronal Activity Changes in an In Vitro MAM Model System of Schizophrenia.
Thériault RK; St-Denis M; Hewitt T; Khokhar JY; Lalonde J; Perreault ML
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073710
[TBL] [Abstract][Full Text] [Related]
2. Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment.
Stark T; Di Bartolomeo M; Di Marco R; Drazanova E; Platania CBM; Iannotti FA; Ruda-Kucerova J; D'Addario C; Kratka L; Pekarik V; Piscitelli F; Babinska Z; Fedotova J; Giurdanella G; Salomone S; Sulcova A; Bucolo C; Wotjak CT; Starcuk Z; Drago F; Mechoulam R; Di Marzo V; Micale V
Biochem Pharmacol; 2020 Jul; 177():114004. PubMed ID: 32360362
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway.
Renard J; Loureiro M; Rosen LG; Zunder J; de Oliveira C; Schmid S; Rushlow WJ; Laviolette SR
J Neurosci; 2016 May; 36(18):5160-9. PubMed ID: 27147666
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats.
Kozela E; Krawczyk M; Kos T; Juknat A; Vogel Z; Popik P
Mol Neurobiol; 2020 Mar; 57(3):1733-1747. PubMed ID: 31823199
[TBL] [Abstract][Full Text] [Related]
5. Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders.
Osborne AL; Solowij N; Babic I; Lum JS; Huang XF; Newell KA; Weston-Green K
Brain Behav Immun; 2019 Oct; 81():574-587. PubMed ID: 31326506
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in neuronal oscillatory activity and memory in the methylazoxymethanol acetate model of schizophrenia.
Albeely AM; Williams OOF; Blight CR; Thériault RK; Perreault ML
Schizophr Res; 2024 May; 267():451-461. PubMed ID: 38643726
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors.
Rodrigues da Silva N; Gomes FV; Sonego AB; Silva NRD; Guimarães FS
Pharmacol Res; 2020 Jun; 156():104749. PubMed ID: 32151683
[TBL] [Abstract][Full Text] [Related]
8. Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia.
Stark T; Ruda-Kucerova J; Iannotti FA; D'Addario C; Di Marco R; Pekarik V; Drazanova E; Piscitelli F; Bari M; Babinska Z; Giurdanella G; Di Bartolomeo M; Salomone S; Sulcova A; Maccarrone M; Wotjak CT; Starcuk Z; Drago F; Mechoulam R; Di Marzo V; Micale V
Neuropharmacology; 2019 Mar; 146():212-221. PubMed ID: 30496751
[TBL] [Abstract][Full Text] [Related]
9. Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia.
Osborne AL; Solowij N; Babic I; Lum JS; Newell KA; Huang XF; Weston-Green K
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Dec; 95():109666. PubMed ID: 31202911
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia.
Levin R; Almeida V; Peres FF; Calzavara MB; da Silva ND; Suiama MA; Niigaki ST; Zuardi AW; Hallak JE; Crippa JA; Abílio VC
Curr Pharm Des; 2012; 18(32):4960-5. PubMed ID: 22716146
[TBL] [Abstract][Full Text] [Related]
11. Iloperidone (Fanapt)--another second-generation antipsychotic.
Med Lett Drugs Ther; 2010 Feb; 52(1332):13-4; quiz 17. PubMed ID: 20208474
[No Abstract] [Full Text] [Related]
12. Iloperidone: A new drug for the treatment of schizophrenia.
Arif SA; Mitchell MM
Am J Health Syst Pharm; 2011 Feb; 68(4):301-8. PubMed ID: 21289324
[TBL] [Abstract][Full Text] [Related]
13. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
Roser P; Vollenweider FX; Kawohl W
World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):208-19. PubMed ID: 20218784
[TBL] [Abstract][Full Text] [Related]
14. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2009 Aug; 63(8):1237-48. PubMed ID: 19624791
[TBL] [Abstract][Full Text] [Related]
15. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.
Citrome L
Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1551-64. PubMed ID: 21034370
[TBL] [Abstract][Full Text] [Related]
16. Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia.
Gururajan A; Taylor DA; Malone DT
Behav Brain Res; 2011 Sep; 222(2):299-308. PubMed ID: 21458498
[TBL] [Abstract][Full Text] [Related]
17. An assessment of iloperidone for the treatment of schizophrenia.
Jain KK
Expert Opin Investig Drugs; 2000 Dec; 9(12):2935-43. PubMed ID: 11093363
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of the antipsychotic properties of cannabidiol in humans.
Iseger TA; Bossong MG
Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice.
Gomes FV; Issy AC; Ferreira FR; Viveros MP; Del Bel EA; Guimarães FS
Int J Neuropsychopharmacol; 2014 Oct; 18(5):. PubMed ID: 25618402
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
